NSE · AJANTPHARM.NS
Ajanta Pharma Limited
₹3,462.00+₹2.30 (+0.07%)
Ajanta Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 8.8% below the high.
Loading market information…
NSE · MARKSANS.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Marksans Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Marksans Pharma Limited’s forward annual dividend is ₹0.90 per share, paid annual. The forward yield is 0.29% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Marksans Pharma Limited’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of ₹3.47. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Marksans Pharma Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The company's extensive product portfolio addresses a wide array of medical needs across numerous therapeutic categories. These include pain management (analgesics), conditions such as benign prostatic hyperplasia and various forms of diabetes, neurological disorders like epilepsy, anti-inflammatory conditions, hyperparathyroidism, and gastrointestinal issues like those requiring antacids or treatments for gastroenterology. Marksans Pharma also develops solutions for cardiovascular health, hormonal imbalances, oncology, gynecology, and hypertension, alongside producing antibiotics, antifungals, antiulceratives, vitamins, dermatological preparations, cephalosporins, injectables, anti-allergy, and antibacterial medications. Furthermore, the firm offers contract research and manufacturing services. Established in 1992, its corporate headquarters are situated in Mumbai, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:00 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| ₹7.09B+1.78% vs estimate |
| Q3 2025 | Feb 11, 2025 | ₹2.45 | ₹6.82B+2.53% vs estimate |
|---|
| Q2 2025 | Nov 12, 2024 | ₹2.15 | ₹6.42B+6.98% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹3,462.00+₹2.30 (+0.07%)
Ajanta Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 8.8% below the high.
₹2,508.70-₹6.40 (-0.25%)
GlaxoSmithKline Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 19.61% below the high.
₹839.00+₹1.65 (+0.2%)
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 9.16% below the high.
₹1,405.00+₹7.60 (+0.54%)
Alivus Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 6.27% below the high.
₹3,691.00-₹68.80 (-1.83%)
Pfizer Limited’s quoted price sits in the lower half of its reported 52-week range, 30.96% below the high.
₹798.65+₹3.80 (+0.48%)
Alembic Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 19.97% below the high.
₹925.60-₹20.40 (-2.16%)
Jubilant Pharmova Limited’s quoted price sits in the lower half of its reported 52-week range, 21.76% below the high.
₹1,053.00-₹44.50 (-4.05%)
Strides Pharma Science Limited’s quoted price sits in the upper half of its reported 52-week range, 16.49% below the high.
